Edition:
United Kingdom

Exact Sciences Corp (EXAS.OQ)

EXAS.OQ on NASDAQ Stock Exchange Capital Market

66.05USD
17 Oct 2018
Change (% chg)

$-1.39 (-2.06%)
Prev Close
$67.44
Open
$67.08
Day's High
$67.31
Day's Low
$65.23
Volume
812,905
Avg. Vol
726,016
52-wk High
$81.22
52-wk Low
$37.39

Chart for

About

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA)... (more)

Overall

Beta: 0.64
Market Cap(Mil.): $5,791.66
Shares Outstanding(Mil.): 119.10
Dividend: --
Yield (%): --

Financials

  EXAS.OQ Industry Sector
P/E (TTM): -- 85.92 33.73
EPS (TTM): -1.29 -- --
ROI: -34.68 0.63 14.31
ROE: -35.62 1.68 16.04

Exact Sciences surges after marketing deal with Pfizer for cancer test

Exact Sciences Corp's shares shot up as much as 26 percent on Wednesday after the company said Pfizer Inc would share marketing expenses and co-promote the company's stool screening test for colorectal cancer.

22 Aug 2018

UPDATE 1-Exact Sciences surges after marketing deal with Pfizer for cancer test

Aug 22 Exact Sciences Corp's shares shot up as much as 26 percent on Wednesday after the company said Pfizer Inc would share marketing expenses and co-promote the company's stool screening test for colorectal cancer.

22 Aug 2018

Exact Sciences signs marketing deal with Pfizer for cancer test

Aug 22 Exact Sciences Corp said on Wednesday Pfizer Inc would share marketing expenses and co-promote the company's stool screening test for colorectal cancer, in a bid to boost sales of the product.

22 Aug 2018

UPDATE 1-American Cancer Society recommends earlier colorectal cancer screening

May 30 The American Cancer Society on Wednesday recommended that people at average risk of colorectal cancer start regular screening at the age of 45 rather than at 50, at a time when studies show a rise in cases of the disease among younger individuals.

30 May 2018

BRIEF-Exact Sciences Says CEO Kevin T. Conroy's 2017 Total Compensation Was $13.3 Million

* EXACT SCIENCES CORP SAYS CEO KEVIN T. CONROY'S 2017 TOTAL COMPENSATION WAS $13.3 MILLION – SEC FILING Source : https://bit.ly/2w2gEbC Further company coverage: (Reuters.Briefs@thomsonreuters.com)

30 Apr 2018

BRIEF-Exact Sciences reports Q1 Loss Per Share of $0.33

* Q1 EARNINGS PER SHARE VIEW $-0.37 -- THOMSON REUTERS I/B/E/S

26 Apr 2018

Competitors

  Price Chg
Quest Diagnostics Inc (DGX.N) $102.38 +0.14
Epigenomics AG (ECXn.F) €1.93 --
GeneNews Ltd (GEN.TO) $0.06 0.00

Earnings vs. Estimates